Skip to main content
. 2022 Oct 14;12:941676. doi: 10.3389/fonc.2022.941676

Table 6.

Clinical characteristics of SCCA patients according to HPV genome status.

  Overall population n=39 Episomal  n=14 Integrated/mixed n=25 p-value
Gender
 Male 7 (17.9%) 2 (14.3%) 5 (20%) 1
 Female 32 (82.1%) 12 (85.7%) 20 (80%)
Age
 Mean (std) 57.5 (8.4) 58.6 (6.6) 56.8 (9.3)
 Median (min-max) 58.2 (38.6-74.9) 59.8 (46.1-71.7) 56.1 (38.6-74.9) 0.6318
 Q1-Q3 51.4-63.8 52.1-63.8 49.4-63.7
Age ≥ 65
 No 32 (82.1%) 13 (92.9%) 19 (76%) 0.3863
 Yes 7 (17.9%) 1 (7.1%) 6 (24%)
ECOG
 0 27 (69.2%) 9 (64.3%) 18 (72%) 0.7232
 1 12 (30.8%) 5 (35.7%) 7 (28%)
HIV positivity
 No 38 (97.4%) 14 (100%) 24 (96%) 1
 Yes 1 (2.6%) 0 (0%) 1 (4%)
T
 Missing (or x) 8 3 5
 0 1 (3.2%) 1 (9.1%) 0 (0%) 0.0590
 1 1 (3.2%) 0 (0%) 1 (5%)
 2 13 (41.9%) 3 (27.3%) 10 (50%)
 3 7 (22.6%) 1 (9.1%) 6 (30%)
 4 9 (29%) 6 (54.5%) 3 (15%)
N
 Missing (or x) 11 5 6
 0 8 (28.6%) 3 (33.3%) 5 (26.3%) 0.4424
 1 5 (17.9%) 0 (0%) 5 (26.3%)
 2 5 (17.9%) 2 (22.2%) 3 (15.8%)
 3 10 (35.7%) 4 (44.4%) 6 (31.6%)
M
 Missing 8 3 5
 0 21 (67.7%) 6 (54.5%) 15 (75%) 0.4232
 1 10 (32.3%) 5 (45.5%) 5 (25%)
RTCT
 No 15 (38.5%) 8 (57.1%) 7 (28%) 0.0727
 Yes 24 (61.5%) 6 (42.9%) 18 (72%)
Surgery
 No 35 (89.7%) 13 (92.9%) 22 (88%) 1
 Yes 4 (10.3%) 1 (7.1%) 3 (12%)
Stage
 Locally advanced 4 (10.3%) 1 (7.1%) 3 (12%) 0.0351
 Synchronous metastasis 12 (30.8%) 8 (57.1%) 4 (16%)
 Metachronous metastasis 23 (59%) 5 (35.7%) 18 (72%)
Invaded sites
 Mean (std) 2.4 (1.3) 2.1 (0.9) 2.6 (1.4)
 Median (min-max) 2 (1-5) 2 (1-4) 2 (1-5) 0.3314
 Q1-Q3 01-mars 01-mars 01-mars
Invaded sites
 1 11 (28.2%) 4 (28.6%) 7 (28%) 0.5195
 2 12 (30.8%) 6 (42.9%) 6 (24%)
 3 9 (23.1%) 3 (21.4%) 6 (24%)
 ≥ 4 7 (17.9%) 1 (7.1%) 6 (24%)
Best L1 response
 Complete response 19 (48.7%) 8 (57.1%) 11 (44%) 0.4310
 Partial response 18 (46.2%) 5 (35.7%) 13 (52%)
 Stability 1 (2.6%) 0 (0%) 1 (4%)
 Progression 1 (2.6%) 1 (7.1%) 0 (0%)